Eli Lilly's Aofugrelone Calcium Tablets Approved for Market Launch

The National Medical Products Administration has approved the market launch of Aofugrelone Calcium Tablets (brand name: Mu You Da), a Class 1 innovative drug submitted by Eli Lilly Nederland B.V. This drug is indicated for long-term weight management in adults with an initial body mass index (BMI) of ≥30 kg/m² (obesity) or ≥27 kg/m² to <30 kg/m² (overweight) with at least one weight-related comorbidity, based on dietary control and increased physical activity. The launch of this drug provides new treatment options for patients.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.